Cargando…

Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients

Axillary lymph node metastases are a key prognostic factor in breast cancer treatment. Our aim was to evaluate how tumor size, tumor location, and imaging results correlate to axillary lymph node diseases for patients with stage I-III HER2/neu+ breast cancer. This is a single-institution retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Englander, Katherine, Chintapally, Neha, Gallagher, Julia, Elleson, Kelly, Sun, Weihong, Whiting, Junmin, Laronga, Christine, Lee, Marie Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047436/ https://www.ncbi.nlm.nih.gov/pubmed/36975428 http://dx.doi.org/10.3390/curroncol30030215

Ejemplares similares

Tumor Characteristics Associated with Axillary Nodal Positivity in Triple Negative Breast Cancer
por: Chintapally, Neha, et al.
Publicado: (2023)

Phosphorylation of Ser(78 )of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer
por: Zhang, Daohai, et al.
Publicado: (2007)

Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis
por: Tong, Zhen-Jun, et al.
Publicado: (2017)

Prognostic value HER-2/neu expression in T1 to T3 breast cancer with axillary lymph node metastasis
por: Maksimovic, S
Publicado: (2009)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
por: Keay, Tyler, et al.
Publicado: (2013)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
por: Ady, N, et al.
Publicado: (2004)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
por: Schlotter, Claus M, et al.
Publicado: (2003)

Upregulation of sialidase NEU3 in head and neck squamous cell carcinoma associated with lymph node metastasis
por: Shiga, Kiyoto, et al.
Publicado: (2015)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

p185(HER‐2/neu) and p21(CIP1/WAF1) Expression in Primary Tumors and Lymph Node Metastases in Non‐small Cell Lung Cancer
por: Akita, Kenji, et al.
Publicado: (2002)

Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer
por: Bahl, A., et al.
Publicado: (2018)

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer
por: Basade, M., et al.
Publicado: (2018)

Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2018)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Impact of Size of the Tumour, Persistence of Estrogen Receptors, Progesterone Receptors, HER2Neu Receptors and Ki67 Values on Positivity of Axillary Lymph Nodes in Patients with Early Breast Cancer with Clinically Negative Axillary Examination
por: Kondov, Borislav, et al.
Publicado: (2017)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
por: Schmidt, Marcus, et al.
Publicado: (2005)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population
por: Osmani, Asif Husain, et al.
Publicado: (2021)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Lymph node density as a surrogate marker for positive lymph nodes
por: Van Gorp, T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iorr0ldjbqtsivckfdl4iok8p0